In plain language
AOD-9604 is a small fragment of human growth hormone that was investigated as a fat-loss agent. Early company-sponsored trials did not show meaningful weight loss beyond placebo, and it was not approved for that use. Today it is sold as a research chemical, and good human evidence for weight benefit is lacking.
What it is explored for
AOD-9604 is an interesting idea: a slice of growth hormone designed to encourage fat metabolism while leaving the hormone's growth and blood-sugar effects behind. That selective, GH-sparing angle is why it keeps drawing attention in body-composition circles. Here is where interest and reported use are highest.
- Body composition and fat metabolism
- Targeting stubborn abdominal and visceral fat
- A growth-hormone approach that spares IGF-1 and blood sugar
- Pairing with GLP-1 protocols for body composition
- Cartilage and joint support (emerging interest)
- Lean, GH-sparing fat-loss support
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited rating, see the evidence summary below for how strong the science actually is.
How it works
AOD-9604 corresponds to the C-terminal fragment of human growth hormone and was designed to influence fat metabolism without the full hormone's growth effects.
- Proposed lipolysis. It was hypothesized to stimulate fat breakdown (lipolysis) and reduce fat formation, based on the parent fragment's activity in early studies.
- Limited receptor clarity. Unlike full growth hormone, it is not thought to raise IGF-1 meaningfully, but its precise targets in humans are not well defined.
The proposed mechanism comes largely from preclinical and early work. Human trials did not confirm a clear weight-loss benefit, so the mechanism's relevance in people is uncertain.
Evidence summary
Human evidence for AOD-9604 as a weight-loss agent is weak. A company-sponsored clinical trial did not show significant weight loss compared with placebo, and it was not approved for obesity. Most remaining claims rest on preclinical data, so the evidence is limited.
Reported safety & side effects
In the trials conducted, AOD-9604 was generally reported as well-tolerated over the short term, but long-term safety, drug interactions, and risks outside of trial settings are not established. It is not an approved medicine.
Frequently asked
Does AOD-9604 cause weight loss?
Human trial evidence does not support meaningful weight loss compared with placebo. Claims of fat loss rest largely on preclinical data, so the benefit in people is not established.
Is it approved?
No. AOD-9604 is not FDA-approved as a weight-loss drug. It is sold as a research chemical.
Does it raise IGF-1 like growth hormone?
It is generally reported not to raise IGF-1 meaningfully, since it is only a fragment of growth hormone, but its precise effects in humans are not well characterized.